Premium
Who benefits from fixed‐dose combinations? Two‐year statin adherence trajectories in initiators of combined amlodipine/atorvastatin therapy
Author(s) -
Schaffer Andrea L.,
Buckley Nicholas A.,
Pearson SallieAnne
Publication year - 2017
Publication title -
pharmacoepidemiology and drug safety
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.023
H-Index - 96
eISSN - 1099-1557
pISSN - 1053-8569
DOI - 10.1002/pds.4342
Subject(s) - amlodipine , medicine , atorvastatin , statin , fixed dose combination , pharmacoepidemiology , logistic regression , combination therapy , pharmacology , urology , blood pressure , medical prescription
Purpose We compared statin adherence in individuals initiating combined amlodipine/atorvastatin therapy as a fixed‐dose (FDC) or free combination and identified subgroups benefiting most from FDCs. Methods We used a 10% sample of Australian Pharmaceutical Benefits Scheme dispensing data (2005‐2015) to identify individuals initiating amlodipine and atorvastatin as an FDC (n = 3996) or free combination (n = 5434), with or without prior statin dispensing. We measured the proportion of days covered in each 30‐day period over 24 months and classified patterns of statin adherence using group‐based trajectory models. We identified predictors of adherence trajectories using logistic regression. Results The median age was 71 years, and 53% were female. We identified 4 patterns of statin adherence: near‐perfect adherence (n = 5383), good adherence (n = 1893), declining adherence (n = 1247), and early nonadherence (n = 907). Compared with the free combination, FDC initiators were more likely to have near‐perfect adherence if they were previously statin adherent irrespective of amlodipine dose (amlodipine 5 mg: OR = 1.61, 95% CI 1.38‐1.87; amlodipine 10 mg: OR = 2.39, 95% CI 1.63‐3.51) or they were previously statin nonadherent and initiated on the 5 mg amlodipine dose (OR = 1.87, 95% CI 1.50‐2.32). Statin‐naïve individuals initiating on the FDC with 10 mg amlodipine were less likely to have near‐perfect adherence (OR = 0.60, 95% CI 0.41‐0.88) and more likely to have early nonadherence (OR = 1.73, 95% CI 1.17‐2.55). Conclusions The amlodipine/atorvastatin FDC was associated with greater statin adherence among prevalent statin users, and individuals who initiated on lower amlodipine doses. The FDCs did not improve adherence in statin‐naïve individuals and in some cases resulted in poorer adherence.